Brief: Hillstream Biopharma Selects Oncobay Clinical To Advance Clinical And Regulatory Development For Its Lead Drug Candidate Hsb-1216, An Anti-Cancer Mechanism
13/04/2023 14:12
April 13 (Reuters) - Hillstream BioPharma Inc HILS.O :
* HILLSTREAM BIOPHARMA SELECTS ONCOBAY CLINICAL TO ADVANCE
CLINICAL AND REGULATORY DEVELOPMENT FOR ITS LEAD DRUG CANDIDATE
HSB-1216, AN ANTI-CANCER MECHANISM
Source text for Eikon: ID:nGNX4ThqHx
Further company coverage: HILS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Canton Strategic Holdings
See all newsBrief: Canton Strategic Holdings, Inc. Expected To Be Included In Russell 3000® And Russell 2000®
Brief: Canton Strategic Authorizes Share Repurchase Program For Up To $50 Million In Common Stock
Canton Strategic Holdings Q1 net loss widens on higher expenses
Brief: Canton Strategic Holdings Reports Full Year 2025 Financial And Operational Results
Brief: Canton Strategic Holdings Inc - Enters Amended Sales Agreement With Clear Street And Virtu Americas - SEC Filing